V-DIG Audit: Johnson & Johnson

Enterprise Technology Stack & Vendor Relationships

Johnson & Johnson’s enterprise technology stack relies primarily on global vendor relationships including Microsoft as a strategic partner for digital surgery solutions ¹. The company’s corporate IT infrastructure is managed through standard enterprise software providers typical of a Fortune 100 pharmaceutical and medical device company.

Israeli-Origin Software & Services: No public evidence identified of Johnson & Johnson holding direct licensing, subscription, or integration relationships with CyberArk, Check Point, SentinelOne, Palo Alto Networks, Wiz, Claroty, NICE, Verint, or comparable Israeli-origin cybersecurity or enterprise software vendors.

Scale of Dependency: No verified evidence of Israeli-origin technology embedded in Johnson & Johnson’s core enterprise infrastructure.

Procurement & Integrator Relationships: No public evidence identified confirming that systems integrators engaged by J&J have mandated, recommended, or deployed Israeli-origin technology as part of named engagements.

Surveillance, Biometrics & Retail Technology

Facial Recognition & Biometrics: No public evidence identified of Johnson & Johnson deploying facial recognition, biometric identification, behavioral analytics, or gait analysis technologies from Israeli-origin vendors including Trigo, AnyVision/Oosto, BriefCam, or comparable vendors. Johnson & Johnson is a pharmaceutical and medical device company and does not operate consumer retail stores in formats that typically deploy frictionless checkout or loss-prevention biometric systems.

Predictive Analytics & Monitoring: No public evidence identified of Johnson & Johnson deploying Israeli-origin predictive policing, sentiment analysis, social media monitoring, or workforce surveillance tools.

Third-Party Deployment: No public evidence identified of Israeli-origin surveillance or biometric technology reaching Johnson & Johnson indirectly via managed security service providers, bundled enterprise suites, or third-party platform integrations.

Cloud Infrastructure, Data Residency & Sovereign Cloud Participation

Data Centre Operations in Israel: No public evidence identified of Johnson & Johnson operating, leasing, or co-locating proprietary data centre infrastructure within Israel.

Government Cloud Contracts: No public evidence identified of Johnson & Johnson participating in Project Nimbus or any comparable Israeli state-backed cloud infrastructure programme. Project Nimbus is a $1.2B cloud contract between Google/Amazon and the Israeli government; J&J is not a party to this contract ².

Data Sovereignty & Resilience Services: Not applicable by company type. Johnson & Johnson does not provide cloud, data sovereignty, or infrastructure resilience services to Israeli state institutions or military bodies.

Defence, Intelligence & Security Sector Technology Relationships

Military & Intelligence Contracts: No public evidence identified of Johnson & Johnson holding contracts, partnerships, or service agreements with the Israeli Ministry of Defence, Israel Defence Forces, Israeli intelligence agencies, or other Israeli state security bodies for IT, communications, data hosting, or analytics services.

Dual-Use Technology Provision: No public evidence identified of Johnson & Johnson’s commercial technology being deployed for military, intelligence, or law enforcement surveillance purposes within Israel or occupied territories.

Offensive Cyber & Weapons Technology: No public evidence identified. Johnson & Johnson does not develop, sell, license, or maintain offensive cyber capabilities, zero-day exploit tools, or digital weapons systems.

AI, Algorithmic & Autonomous Systems

AI/ML Provision to State Bodies: No public evidence identified of Johnson & Johnson providing AI, ML, computer vision, or autonomous decision-support systems to Israeli state, military, or security bodies. J&J MedTech established a strategic partnership with Microsoft (announced January 2022) making Microsoft Azure the preferred cloud provider for digital surgery solutions, using Azure, AI, ML, Azure IoT, and Edge Computing. This partnership is a commercial B2B relationship; no evidence indicates it involves Israeli state customers ¹.

Training Data & Model Development: No public evidence identified of Johnson & Johnson’s AI models or platforms being trained on, or provided access to, civilian population data, intercepted communications, or surveillance-derived datasets originating from Israel or occupied territories.

Autonomous Systems & Lethality: No public evidence identified. Johnson & Johnson’s robotics portfolio (Ottava surgical robot, Monarch bronchoscopy platform) is clinical in application.

Technology Ecosystem & R&D Footprint

Israeli R&D Centres: Johnson & Johnson’s Biosense Webster subsidiary maintains R&D and manufacturing operations in Yokneam, Israel, serving as the global Technology Center for cardiac electrophysiology and mapping systems. This facility was established through J&J’s 1998 acquisition of Biosense Webster; operations are confirmed as ongoing ³. Johnson & Johnson acquired Israeli medical device company V-Wave in October 2024 for $600M upfront (potential $1.7B total). V-Wave develops the Ventura Interatrial Shunt for heart failure treatment—a civilian medical device ⁴⁵. JLABS listings show no physical site in Israel; the 2014 announcement described plans for a public-private biotechnology incubator near Weizmann Science Park, Rehovot, but current JLABS EMEA operates as a virtual-only incubator where Israeli companies can join as virtual members ⁶⁷⁸. Johnson & Johnson Innovation (JJDC) maintains active investment in Israeli medtech and pharma through principals based in Israel, including Gilad Glick, VP Venture Investments, and Amir Blatt, Principal Venture Investments ⁹¹⁰.

Acquisitions & Investments: Johnson & Johnson acquired Biosense Webster in 1998, an Israeli-origin electrophysiology company with ongoing operations in Israel ³. J&J acquired Itamar Medical in 2021 (closed 2022) for approximately $538M, an Israeli medical technology company specializing in cardiovascular diagnostics; Itamar Medical was subsequently sold to ZOLL Medical (Asahi Kasei) in 2022 ¹¹. J&J acquired V-Wave Ltd. in October 2024, an Israeli heart failure device company ⁴⁵.

Patent & Intellectual Property: No public evidence identified of specific patent co-development arrangements or licensing agreements between Johnson & Johnson and Israeli research institutions (Technion, Hebrew University, Weizmann Institute).

Civil Society Scrutiny & Regulatory History

NGO & Academic Reports: The UN OHCHR Business Enterprise Database contains 158 business enterprises involved in settlement-related activities. No direct evidence identified confirming Johnson & Johnson appears in this database ¹². The June 2025 UN Special Rapporteur report on “economy of genocide” (A/HRC/59/23) names multiple technology and commercial companies; no specific mention of Johnson & Johnson was found in searches ¹³. Direct query of Who Profits for “Johnson & Johnson” returned no dedicated company profile in search results. Magalcom, an Israeli IT services provider, lists Johnson & Johnson among its commercial clients; however, Magalcom also holds $185M in contracts with Israeli Ministry of Defense (2020) ¹⁴.

Boycott & Divestment Campaigns: Multiple BDS campaign materials explicitly target Johnson & Johnson, citing the company’s ownership of operations in Israel. BDS India and other groups identify J&J as a boycott target ¹⁵.

Regulatory & Legal Actions: No public evidence identified of regulatory inquiries, legal challenges, export control actions, or sanctions-related investigations involving Johnson & Johnson’s technology sales or services to Israeli state entities.

Controlling Principals: Marillyn A. Hewson serves on Johnson & Johnson Board of Directors; she is former Chairman, President and CEO of Lockheed Martin Corporation, a major US defense contractor with extensive Israeli military partnerships ¹⁶. Daniel Pinto, President of JPMorganChase, was elected to J&J Board in 2025 ¹⁷. Gilad Glick serves as VP Venture Investments at Johnson & Johnson Innovation; he is former CEO of Itamar Medical with no defense or intelligence affiliations identified ⁹¹¹. Amir Blatt serves as Principal, Venture Investments at J&J Innovation, based in Shefayim, Israel; he was formerly founding partner of Almeda Ventures (healthcare VC) with no defense or intelligence affiliations identified ¹⁰.

Major Shareholders: Top institutional shareholders include Vanguard (9.8%), BlackRock (5.4%), and State Street (5.5%) ¹⁸. Lockheed Martin Investment Management acquired J&J shares in May 2026 ¹⁹. No specific Israeli defense or surveillance investments were found in these funds. No public evidence identified of any controlling principals (≥10% shareholders) having personal equity stakes, board roles, or personal investments in Israeli surveillance, cyber, AI, or military-tech firms.

End Notes